Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2007 October;98(5) > Minerva Medica 2007 October;98(5):603-23

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

REVIEWS  


Minerva Medica 2007 October;98(5):603-23

language: English, Italian

Targeted therapies in solid tumours: results and promises

Pantaleo M. A., Saponara M., Nannini M., Biasco G.

“L. and A. Seragnoli” Institute of Medical Hematology and Oncology S. Orsola-Malpighi Polyclinic, Bologna, Italy


PDF  


In these last few years novel approaches to the treatment of solid tumours have been proposed. Therapeutic agents addressed to specific functions of the neoplastic cells seems to be very promising tools, with a low grade of toxicities. These agents are the basis of the so called targeted therapies. Small molecules inhibiting the proliferative cascade of the cancer cells and monoclonal specific antibodies against growth factor or vascular endothelial growth factor have been claimed as the promise in cancer therapy. Unfortunately, the very good results obtained in preclinical experiments have not been completely confirmed in the clinical practice. A selection of patients who could have beneficial effects from the novel agents is mandatory to avoid inappropriate therapies and also unjustified expenses.

top of page

Publication History

Cite this article as

Corresponding author e-mail